Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Kelly F Bell"'
Autor:
Alexander Slowley, Kelesitse Phiri, Jasjit K. Multani, Vicky Casey, Sheila Mpima, Marie Yasuda, Chi‐Chang Chen, Fil Manuguid, Jessica Chao, Amine Aziez, Kelly F. Bell, Alexander Stojadinovic
Publikováno v:
Thoracic Cancer, Vol 14, Iss 28, Pp 2846-2858 (2023)
Abstract Background Real‐world evidence is increasingly used to guide treatment and regulatory decisions for non‐small cell lung cancer (NSCLC). Real‐world treatment patterns and clinical outcomes among patients with advanced/metastatic NSCLC i
Externí odkaz:
https://doaj.org/article/2bafcf605a8c49ab901542b701ab65ea
Publikováno v:
Journal of Medical Economics. 21:497-509
To compare 1-year costs and benefits of dapagliflozin (DAPA), a sodium-glucose cotransporter-2 (SGLT-2) inhibitor, with those of other treatments for type 2 diabetes (T2D), such as glucagon-like peptide-1 receptor agonists (GLP-1RAs), sulfonylureas (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf18c0459f015ba7101fb9119f9d6ee1
https://doi.org/10.1080/13696998.2018.1434182
https://doi.org/10.1080/13696998.2018.1434182
Autor:
Eric T, Wittbrodt, James M, Eudicone, Kelly F, Bell, Devin M, Enhoffer, Keith, Latham, Jennifer B, Green
Publikováno v:
The American journal of managed care. 25(4)
The authors of the manuscript "Generalizability of Glucagon-Like Peptide-1 Receptor Agonist Cardiovascular Outcome Trials Enrollment Criteria to the US Type 2 Diabetes Population" respond to a letter to the editor.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e48bb9ac3c210ac2eb1edffab32ccb05
https://pubmed.ncbi.nlm.nih.gov/30986012
https://pubmed.ncbi.nlm.nih.gov/30986012
Publikováno v:
Expert review of endocrinologymetabolism. 9(2)
Hypoglycemia is a limiting factor in the management of diabetes. Studies comparing oral antidiabetic medications are needed to identify treatment options that can help clinicians and patients minimize their associated hypoglycemia risk. The purpose o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2175fefa595a3d0a255432d000857e12
https://pubmed.ncbi.nlm.nih.gov/30743760
https://pubmed.ncbi.nlm.nih.gov/30743760
Publikováno v:
Risk Management and Healthcare Policy
Background The use of quality measures attempts to improve safety and health outcomes and to reduce costs. In two Phase III trials in treatment-naive patients with type 2 diabetes, dapagliflozin 5 or 10 mg/d as initial combination therapy with metfor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38768a1f88dc7ab54241e1a22521c124
https://doi.org/10.2147/rmhp.s108586
https://doi.org/10.2147/rmhp.s108586
Autor:
Stephen S. Johnston, Kelly F Bell, C. Sternhufvud, Donna McMorrow, J Mukherjee, Marni Stott-Miller, Nancy Smith
Publikováno v:
Journal of Managed Care & Specialty Pharmacy. 22:449-466
Previous research suggests that weight loss is associated with decreases in health care costs among individuals with type 2 diabetes mellitus (T2DM) and that weight change can affect clinical measures, including hemoglobin A1c (A1c), low-density lipo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dd6148e7ff480485dd33c34555fce322
https://doi.org/10.18553/jmcp.2016.22.5.449
https://doi.org/10.18553/jmcp.2016.22.5.449
Autor:
Huan, Huang, Kelly F, Bell, Ray, Gani, Cathy W, Tugwell, James M, Eudicone, Michelle R, Krukas-Hampel
Publikováno v:
The American journal of managed care. 24
The efficacy of dapagliflozin as add-on therapy to metformin has been assessed in randomized trials. However, its effectiveness has not been assessed in a US real-world setting.Electronic medical record (EMR) data were used to compare clinical outcom
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::dc762a4d0572e701a6b5a740fea6c349
https://pubmed.ncbi.nlm.nih.gov/29693359
https://pubmed.ncbi.nlm.nih.gov/29693359
Autor:
Eric T, Wittbrodt, James M, Eudicone, Kelly F, Bell, Devin M, Enhoffer, Keith, Latham, Jennifer B, Green
Publikováno v:
The American journal of managed care. 24
Cardiovascular outcomes trials (CVOTs) for evaluating the safety of novel antidiabetic agents are required by the FDA. CVOTs vary in their design and inclusion criteria, making it difficult to evaluate their applicability to the general population. T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::80f3f54238d514486e5ef86029db4e5b
https://pubmed.ncbi.nlm.nih.gov/30986013
https://pubmed.ncbi.nlm.nih.gov/30986013
Autor:
Eric T, Wittbrodt, James M, Eudicone, Kelly F, Bell, Devin M, Enhoffer, Keith, Latham, Jennifer B, Green
Publikováno v:
The American journal of managed care. 24
Guidance to industry from the FDA requires studies to evaluate the cardiovascular safety of novel type 2 diabetes (T2D) medications. Although the objectives of such cardiovascular outcomes trials (CVOTs) are similar, differences in features such as e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::b7b47559786277b6bb76beb8a1a305bc
https://pubmed.ncbi.nlm.nih.gov/29693360
https://pubmed.ncbi.nlm.nih.gov/29693360
Autor:
D Enhoffer, Kelly F Bell, K Latham, Eric Wittbrodt, James M. Eudicone, Jennifer B. Green, M Kuske
Publikováno v:
Diabetologie und Stoffwechsel.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6545664929b2558916dfdf145c8c3b5e
https://doi.org/10.1055/s-0038-1641967
https://doi.org/10.1055/s-0038-1641967